Shares of Veru Inc.
VERU,
rocketed 175% toward a 13-month high in afternoon trading Monday, after biopharmaceutical company announced positive results from its Phase 3 trial of its oral COVID-19 treatment. Trading volume spiked up to 264.2 million shares, compared with the full-day average of about 629,400 shares, and enough to make the stock the most actively traded on major U.S. exchanges. Veru said patients hospitalized with moderate to severe COVID-19, who were at high risk for adult respiratory distress syndrome (ARDS) and death, its oral sabizabulin led to a “clinically and statistically meaningful” 55% reduction in deaths. The Independent Data Safety Monitoring Committee “unanimously” recommended the Phase 3 trial be halted early because of efficacy, with no safety concerns identified. Veru’s stock, which had closed at a 16-month low on Friday, has now run up 103.4% year to date, while the iShares Biotechnology ETF
ក្រុមហ៊ុន IBB,
បានធ្លាក់ចុះ ១១,២% និង S&P 14.1
SPX,
បាត់បង់ 7.0%។
Source: https://www.marketwatch.com/story/verus-stock-rockets-after-oral-covid-19-treatment-leads-to-statistically-meaningful-reduction-in-deaths-2022-04-11?siteid=yhoof2&yptr=yahoo